Altamira Therapeutics

CYTOPre-clinical

Altamira Therapeutics is a diversified biotech holding company with a strategic focus on RNA delivery, allergy care, and central nervous system disorders. Its core technology is the xPhore™ platform, a peptide-based nanoparticle system designed for efficient nucleic acid delivery to tissues outside the liver, applicable to siRNA, mRNA, circRNA, and DNA. The company has commercialized Bentrio®, a drug-free nasal spray for allergic rhinitis, while advancing its CNS pipeline through Otolanum AG, positioning itself across both near-term revenue and long-term therapeutic development.

Focus

RNA & Gene Therapy

CYTO · Stock Price

USD 0.30+0.00 (+0.00%)

Historical price data

AI Company Overview

Technology Platform

The xPhore™ platform is a peptide-based nanoparticle technology designed for efficient delivery of various nucleic acid modalities (siRNA, mRNA, circRNA, DNA) to extrahepatic tissues, addressing a key limitation in RNA therapeutics.

Funding History

Total raised: $9M

PIPE$3.8MUndisclosedJun 15, 2022

PIPE$5.2MUndisclosedNov 15, 2021

Opportunities

Major opportunities include securing high-value licensing deals for the xPhore™ RNA delivery platform with large biopharma partners, scaling commercial sales of Bentrio® in the global allergic rhinitis market, and successfully advancing novel CNS therapies for high-unmet-need conditions like hearing loss through the Otolanum AG pipeline.

Risk Factors

Key risks include severe financial constraints as a micro-cap company, the need to clinically validate and monetize the xPhore™ platform, intense competition in the OTC allergy market limiting Bentrio®'s commercial success, and the high failure rate inherent in early-stage neurological drug development.

Competitive Landscape

Altamira competes with established RNA delivery firms and large pharma in nucleic acid therapeutics, with numerous OTC and prescription brands in allergic rhinitis, and with a crowded field of biotechs in CNS disorders. Its differentiation lies in xPhore™'s focus on extrahepatic delivery, Bentrio®'s drug-free formulation, and a diversified portfolio balancing near-term revenue with long-term platform potential.